As a member of the Pharmacokinetics & Drug Metabolism (PKDM) organization for over 8 years, Kip’s research is focused on the definition of drug properties that impact in vivo disposition (ADMET: absorption, distribution, metabolism, excretion and toxicity). Using both in vitro assays, as well as pre-clinical animal models, the group’s efforts are rooted in translational approaches to project clinical expectations of PK/PD. In addition to Kip’s role as a project team representative across both large and small molecule programs, he is an active member of the Cellular and Protein Interactions sub-team that emphasizes cell-based and a variety of biophysical assay approaches to identify potential pharmacokinetic liabilities.
Conner, K. P., et al. (2020). "Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues." MAbs 12(1): 1746520.
Conner, K. P., et al. (2020). "The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation." Pharmacology & Therapeutics 212: 107574.
Conner, K. P., et al. (2014). "Evaluation of Near Infrared Fluorescent Labeling of Monoclonal Antibodies as a Tool for Tissue Distribution." Drug Metabolism and Disposition 42(11): 1906-1913.
Conner, K. P., et al. (2011). "Interactions of cytochrome P450s with their ligands." Arch Biochem Biophys 507(1): 56-65.
Ph.D., Medicinal and Pharmaceutical Chemistry, University of Washington
B.S., Biochemistry, San Francisco State University